Monoclonal antibodies to clostridia glutamate dehydrogenase
ViroStat has announces the release of new monoclonal antibody pairs to clostridia glutamate dehydrogenase (GDH), validated by enzyme-linked immunosorbent assay (ELISA). These antibodies represent a new set of tools for rapid detection.
Clostridium difficile-associated diarrhoea (CDAD) is the leading cause of nosocomial diarrhoea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces. Thus, rapid detection is crucial to its control. Most rapid tests target the toxins (A & B) produced during the infection.
Another diagnostic target is GDH, an enzyme produced and released during bacterial growth. Studies have shown that adding GDH detection together with toxin detection by enzyme-linked immunoassay (EIA) or polymerase chain reaction (PCR) significantly improves assay specificity.
ViroStat is a primary manufacturer, supplying infectious disease reagents to researchers and rapid test manufacturers. Data sheets for these antibodies can be downloaded from the company website, as can a copy of the new ViroStat catalogue.
The British In Vitro Diagnostics Association represents the IVD Industry in the UK, to Government, professional bodies, the public, and at MedTech Europe. Giving support to members on regulatory issues, BIVDA also promotes the clinical and cost utility of IVDs in the provision of effective healthcare, both in acute diagnosis and in the prediction...